(NASDAQ: IMMP) Immutep's forecast annual revenue growth rate of 216.65% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 113.79%, and it is also forecast to beat the US market's average forecast revenue growth rate of 23.49%.
Immutep's revenue in 2026 is $6,708,683.On average, 5 Wall Street analysts forecast IMMP's revenue for 2026 to be $28,909,872,027, with the lowest IMMP revenue forecast at $5,724,727,134, and the highest IMMP revenue forecast at $53,975,998,692. On average, 4 Wall Street analysts forecast IMMP's revenue for 2027 to be $13,864,938,625, with the lowest IMMP revenue forecast at $5,724,727,134, and the highest IMMP revenue forecast at $22,694,453,996.
In 2028, IMMP is forecast to generate $376,123,335,041 in revenue, with the lowest revenue forecast at $131,668,724,082 and the highest revenue forecast at $640,964,984,468.